CPC, LLC has made a significant update by filing an amendment to its previous offering, which underscores its ongoing commitment to its investment strategy. This amendment is crucial as it reflects the company's approach to adapting to the evolving investment landscape.
Founded in Kansas, CPC, LLC operates as a limited liability company and is primarily involved in the investment sector. The company is located at 1511 Baltimore Ave., Suite 500, Kansas City, Missouri. It has been active in filing with the SEC, with its most recent filings including a D/A form on October 30, 2026, and previous amendments dating back to the same month in 2025 and 2024.
The recent filing, accession number 0001398344-26-019100, indicates that CPC is utilizing Rule 506(b) to provide a "safer harbor" for its private offering. This rule allows for certain exemptions under the Investment Company Act, specifically sections 3(c) and 3(c)(7), which pertain to pooled investment funds. The filing also notes that the total amount sold to date stands at $300,475,000, with the total offering amount remaining indefinite.
This update may have implications for various stakeholders, including current and potential investors, as well as industry competitors. With 62 investors already involved, the company is clearly establishing a foothold in the investment market. The filing shows that CPC does not accept non-accredited investors, focusing instead on a more exclusive group.
Looking ahead, the filing does not specify what actions will follow this amendment. However, CPC's ongoing commitment to performance-based compensation and its quarterly capital contributions to CPC Management suggest a proactive approach to managing investor relations and fund performance.
Read Next
Workers United Files to Sell $8.4 Million in Amalgamated Stock
Carvana Co. files to sell 10 million shares of stock
Platford Giles Richard to Sell 55,617 Takeda Shares
Takeda's Teresa Bitetti to Sell 46,609 Shares Amid Tax Obligations
Kiniksa Pharmaceuticals reports significant stock sale by officer
Moat Ross to Sell Over 103,000 Shares of Kiniksa Pharmaceuticals










